EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies

Jonathan E Campbell iD, Daniel J Drucker iD

Diabetes · 01.08.2025 · 74 (8) · 1320-1325

DOI: 10.2337/db25-0393 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, online erschienen am 16.06.2025. Verfasst von Jonathan E Campbell und 1 weiteren Autor:innen. Beteiligte Einrichtung: Duke Molecular Physiology Institute, Durham, NC. Hauptthemen laut MEDLINE: Receptors, Gastrointestinal Hormone, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current and emerging strategies to therapeutically target weight management include pairing agonism of the glucagon-like peptide 1 receptor (GLP-1R) with either agonism or antagonism of the glucose-dependent insulinotropic polypeptide receptor (GIPR). On the surface, these two approaches seem contradictory, yet they have produced similar effects for weight loss in clinical studies. Arguments that support the rationale for both approaches are made in these point-counterpoint articles, founded on preclinical studies, human genetics, and clinical outcomes. Here, we attempt to reconcile how two opposing approaches can produce similar effects on body weight by evaluating the leading hypotheses derived from the available evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Gastrointestinal HormoneGlucagon-Like Peptide-1 Receptor AgonistsObesityHumansAnimalsGlucagon-Like Peptide-1 ReceptorWeight LossGastric Inhibitory Polypeptide

Substanzen

Receptors, Gastrointestinal Hormonegastric inhibitory polypeptide receptorGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorGastric Inhibitory Polypeptide

Autor:innen und Institutionen

  • Duke Molecular Physiology Institute, Durham, NC.
  • Lunenfeld-Tanenbaum Research Institute, Sinai Health System, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Jonathan E Campbell, Daniel J Drucker

Förderung

  • NIDDK NIH HHS
  • CIHR
  • Canadian Institutes of Health Research
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Campbell, J. E., & Drucker, D. J. (2025). Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies. Diabetes, 74(8), 1320-1325. https://doi.org/10.2337/db25-0393

Vancouver

Campbell JE, Drucker DJ. Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies. Diabetes. 2025;74(8):1320-1325. doi:10.2337/db25-0393

BibTeX
@article{Campbell2025,
  author = {Campbell, Jonathan E and Drucker, Daniel J},
  title = {Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies},
  journal = {Diabetes},
  year = {2025},
  volume = {74},
  number = {8},
  pages = {1320--1325},
  doi = {10.2337/db25-0393}
}
Kostenlos starten →